UNIQUE THIOREDOXIN INHIBITORS AS ANTI-CANCER DRUGS
UNIQUE THIOREDOXIN INHIBITORS AS ANTI-CANCER DRUGS
批准号:
6294814
负责人:
LYNN KIRKPATRICK
金额:
$18.89万
依托单位国家:
美国
项目类别:
财政年份:
2001
资助国家:
美国
项目状态:
已结题
起止时间:
2001-02-01 至 2003-01-31
中文摘要
描述:ProlX制药公司已经证明硫氧还蛋白具有
英文摘要
DESCRIPTION: ProlX Pharmaceutical has demonstrated that thioredoxin has an
important role in maintaining the transformed phenotype of some human cancers
as well as their resistance to chemotherapeutic drugs and is thus a highly
rational target for novel cancer drug development. The studies described
herein, suggest that thioredoxin is a human anti apoptosis and oncogene that is
overexpressed by a number of human cancers. ProlX has exclusive worldwide
rights to develop the thioredoxin target and is dedicated to exploiting these
observations and rapidly developing agents that selectively disrupt this novel
signal transduction pathway. The objective of this Phase I proposal is to
develop novel inhibitors of thioredoxin redox system based on a new
pharmacophore, identified from the NCI database using ProlX lead compound
activities in the 60 cell lines screen and the COMPARE analyses. The Specific
Aims of the proposal are 1) to synthesis selective inhibitors of the
thioredoxin system using combinatorial chemistry for lead optimization; 2) to
investigate the specificity of the compounds for thioredoxin/thioredoxin
reductase signaling in vitro; and 3) to evaluated the most active analogues for
anti-tumor activity in vivo. These studies will provide novel lead anticancer
candidates for further preclinical development, including toxicology,
pharmacokinetic studies and the eventual Phase I clinical trial, which will be
the subject of a future Phase II application.
PROPOSED COMMERCIAL APPLICATION:
One is every four deaths in the US is doe to cancer. The overall cancer drug market exceeds
$2 billion in the USA. There is significant need to identify novel and selective small molecule-
based cancer therapies. This proposal seeks to undertake the synthesis of a chemical library
of thioether analogues as potential anticancer drugs, which through thioredoxin inhibition
would provide novel therapies against breast, lung, colon and gastric cancer, all which
have been found to have elevated thioredoxin levels.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Anticancer redox inhibitor,Pleurotin
-
批准号:6879258
-
项目类别:
-
资助金额:$19.36万
-
财政年份:2005
-
负责人:LYNN KIRKPATRICK
-
依托单位:
PI-3 kinase inhibitor PX-866 as anticancer therapy
-
批准号:7159438
-
项目类别:
-
资助金额:$79.09万
-
财政年份:2005
-
负责人:LYNN KIRKPATRICK
-
依托单位:
PI-3 kinase inhibitor PX-866 as anticancer therapy
-
批准号:6932660
-
项目类别:
-
资助金额:$19.12万
-
财政年份:2005
-
负责人:LYNN KIRKPATRICK
-
依托单位:
PI-3 kinase inhibitor PX-866 as anticancer therapy
-
批准号:7263198
-
项目类别:
-
资助金额:$83.58万
-
财政年份:2005
-
负责人:LYNN KIRKPATRICK
-
依托单位:
PX-12, A Molecularly Targeted Preventive Agent
-
批准号:6780811
-
项目类别:
-
资助金额:$20.61万
-
财政年份:2004
-
负责人:LYNN KIRKPATRICK
-
依托单位:
PX-12, A Molecularly Targeted Preventive Agent
-
批准号:6882615
-
项目类别:
-
资助金额:$19.97万
-
财政年份:2004
-
负责人:LYNN KIRKPATRICK
-
依托单位:
CELLECTARRAY FOR CANCER DRUG DEVELOPMENT
-
批准号:6209516
-
项目类别:
-
资助金额:$25.9万
-
财政年份:2000
-
负责人:LYNN KIRKPATRICK
-
依托单位:
A Hypoxia Activated HIF-1 & Inhibitor for Cancer Therapy
-
批准号:6918549
-
项目类别:
-
资助金额:$65.0万
-
财政年份:1998
-
负责人:LYNN KIRKPATRICK
-
依托单位:
A Hypoxia Activated HIF-1 & Inhibitor for Cancer Therapy
-
批准号:6479873
-
项目类别:
-
资助金额:$64.88万
-
财政年份:1998
-
负责人:LYNN KIRKPATRICK
-
依托单位:
NOVEL BIOREDUCTIVELY ACTIVATED ALKYLATING AGENTS
-
批准号:2645331
-
项目类别:
-
资助金额:$10.0万
-
财政年份:1998
-
负责人:LYNN KIRKPATRICK
-
依托单位:
A Hypoxia Activated HIF-1 & Inhibitor for Cancer Therapy
-
批准号:6619418
-
项目类别:
-
资助金额:$64.96万
-
财政年份:1998
-
负责人:LYNN KIRKPATRICK
-
依托单位:
A Hypoxia Activated HIF-1 & Inhibitor for Cancer Therapy
-
批准号:6796381
-
项目类别:
-
资助金额:$62.98万
-
财政年份:1998
-
负责人:LYNN KIRKPATRICK
-
依托单位:
NOVEL ANTITUMOR DISULFIDES
-
批准号:2903455
-
项目类别:
-
资助金额:$50.7万
-
财政年份:1997
-
负责人:LYNN KIRKPATRICK
-
依托单位:
Thioredoxin Inhibitor, PX-12, in Phase II Clinical Trial
-
批准号:7051569
-
项目类别:
-
资助金额:$99.69万
-
财政年份:1997
-
负责人:LYNN KIRKPATRICK
-
依托单位:
NOVEL ANTITUMOR DISULFIDES
-
批准号:6643009
-
项目类别:
-
资助金额:$11.68万
-
财政年份:1997
-
负责人:LYNN KIRKPATRICK
-
依托单位:
NOVEL ANTITUMOR DISULFIDES
-
批准号:6172712
-
项目类别:
-
资助金额:$69.87万
-
财政年份:1997
-
负责人:LYNN KIRKPATRICK
-
依托单位:
NOVEL ANTITUMOR DISULFIDES
-
批准号:6513132
-
项目类别:
-
资助金额:$65.4万
-
财政年份:1997
-
负责人:LYNN KIRKPATRICK
-
依托单位:
NOVEL ANTITUMOR DISULFIDES
-
批准号:6376548
-
项目类别:
-
资助金额:$43.83万
-
财政年份:1997
-
负责人:LYNN KIRKPATRICK
-
依托单位:
Thioredoxin Inhibitor, PX-12, in Phase II Clinical Trial
-
批准号:7265290
-
项目类别:
-
资助金额:$99.54万
-
财政年份:1997
-
负责人:LYNN KIRKPATRICK
-
依托单位:
海外基金